Tymlos, Evenity Pricing: Should Generic Zoledronic Be Reference Point?
Executive Summary
ICER draft report concluding data are insufficient to distinguish the effectiveness of anabolic treatments for osteoporosis from generic zoledronic acid raises questions about price premiums for the newer treatments.
You may also be interested in...
Radius Prices Osteoporosis 'Blockbuster' Tymlos To Compete, Grow Market
At $19,500 per year, Radius Health's Tymlos (abaloparatide) is priced to compete with Lilly's similar, but well-established drug Forteo. The company hopes to increase the size of the osteoporosis market to achieve its blockbuster sales goal, but at least one analyst has her doubts.
Xtandi Pricing and Patents: Alternatives To March-In Urged To Lower Medicare, Medicaid Costs
The timing of the request, with Xtandi’s loss of exclusivity on the horizon, could be explained by the concern that a change in the US presidential administration in 2025 may limit the prospects for near-term relief.
Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?
Insurance plans put on notice that CMS is concerned about restrictions on drugs with negotiated prices, but it’s not clear what the agency can or will do about it.